Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brands: ARISTADA, ARISTADA INITIO
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Aripiprazole lauroxil (Aristada) is a long-acting injectable prodrug of aripiprazole indicated for schizophrenia.
It provides extended dosing intervals (monthly through every 2 months depending on strength). As with other depot antipsychotics, real-world benefit depends heavily on clinic workflow: reliable injection scheduling, missed-dose protocols, and clear documentation.
Compared with many SGAs, aripiprazole-class partial agonists tend to have lower prolactin burden and often lower sedation, but Akathisia/restlessness and insomnia can limit tolerability.
For interval comparisons and oral overlap options, see the LAI Navigator.
Aripiprazole lauroxil is chosen when teams want a partial-agonist option with longer intervals than monthly dosing. The long terminal half-life supports adherence but makes adverse effects slower to resolve after dose changes, so many clinics emphasize early tolerability checks during initiation.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
After conversion to aripiprazole, pharmacology mirrors the parent drug: dopamine D2/D3 partial agonism with serotonin 5-HT1A partial agonism and 5-HT2A antagonism.
Partial agonism can attenuate hyperdopaminergic pathways linked to positive symptoms while supporting cortical dopaminergic tone relevant to negative symptoms.